# Impact of Recombinant Human Growth Hormone on HIV Persistence

> **NCT03091374** · PHASE2 · COMPLETED · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 22 (actual)

## Conditions studied

- Human Immunodeficiency Virus
- Growth Hormone Treatment

## Interventions

- **DRUG:** Somatotropin (Human)

## Key facts

- **NCT ID:** NCT03091374
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2021-03
- **Final completion:** 2024-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03091374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03091374, "Impact of Recombinant Human Growth Hormone on HIV Persistence". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03091374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*